279 related articles for article (PubMed ID: 12869391)
1. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
MacInnes A; Fairman DA; Binding P; Rhodes Ja; Wyatt MJ; Phelan A; Haddock PS; Karran EH
Circ Res; 2003 Aug; 93(3):e26-32. PubMed ID: 12869391
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase.
Lopaschuk GD; Barr R; Thomas PD; Dyck JR
Circ Res; 2003 Aug; 93(3):e33-7. PubMed ID: 12869392
[TBL] [Abstract][Full Text] [Related]
3. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
Kantor PF; Lucien A; Kozak R; Lopaschuk GD
Circ Res; 2000 Mar; 86(5):580-8. PubMed ID: 10720420
[TBL] [Abstract][Full Text] [Related]
4. The effects of chronic trimetazidine treatment on mechanical function and fatty acid oxidation in diabetic rat hearts.
Onay-Besikci A; Guner S; Arioglu E; Ozakca I; Ozcelikay AT; Altan VM
Can J Physiol Pharmacol; 2007 May; 85(5):527-35. PubMed ID: 17632588
[TBL] [Abstract][Full Text] [Related]
5. A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion.
Wang P; Fraser H; Lloyd SG; McVeigh JJ; Belardinelli L; Chatham JC
J Pharmacol Exp Ther; 2007 Apr; 321(1):213-20. PubMed ID: 17202401
[TBL] [Abstract][Full Text] [Related]
6. Early administration of trimetazidine may prevent or ameliorate diabetic cardiomyopathy.
Wenmeng W; Qizhu T
Med Hypotheses; 2011 Feb; 76(2):181-3. PubMed ID: 20932648
[TBL] [Abstract][Full Text] [Related]
7. Trimetazidine normalizes postischemic function of hypertrophied rat hearts.
Saeedi R; Grist M; Wambolt RB; Bescond-Jacquet A; Lucien A; Allard MF
J Pharmacol Exp Ther; 2005 Jul; 314(1):446-54. PubMed ID: 15840766
[TBL] [Abstract][Full Text] [Related]
8. Protective effect of trimetazidine on myocardial mitochondrial function in an ex-vivo model of global myocardial ischemia.
Monteiro P; Duarte AI; Gonçalves LM; Moreno A; Providência LA
Eur J Pharmacol; 2004 Oct; 503(1-3):123-8. PubMed ID: 15496306
[TBL] [Abstract][Full Text] [Related]
9. Treatment with the 3-ketoacyl-CoA thiolase inhibitor trimetazidine does not exacerbate whole-body insulin resistance in obese mice.
Ussher JR; Keung W; Fillmore N; Koves TR; Mori J; Zhang L; Lopaschuk DG; Ilkayeva OR; Wagg CS; Jaswal JS; Muoio DM; Lopaschuk GD
J Pharmacol Exp Ther; 2014 Jun; 349(3):487-96. PubMed ID: 24700885
[TBL] [Abstract][Full Text] [Related]
10. Optimizing cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated?
Lopaschuk GD
Coron Artery Dis; 2001 Feb; 12 Suppl 1():S8-11. PubMed ID: 11286307
[TBL] [Abstract][Full Text] [Related]
11. Cardioprotective effects of trimetazidine: a review.
Marzilli M
Curr Med Res Opin; 2003; 19(7):661-72. PubMed ID: 14606990
[TBL] [Abstract][Full Text] [Related]
12. Trimetazidine therapy prevents obesity-induced cardiomyopathy in mice.
Ussher JR; Fillmore N; Keung W; Mori J; Beker DL; Wagg CS; Jaswal JS; Lopaschuk GD
Can J Cardiol; 2014 Aug; 30(8):940-4. PubMed ID: 25064584
[TBL] [Abstract][Full Text] [Related]
13. Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation.
Dyck JR; Cheng JF; Stanley WC; Barr R; Chandler MP; Brown S; Wallace D; Arrhenius T; Harmon C; Yang G; Nadzan AM; Lopaschuk GD
Circ Res; 2004 May; 94(9):e78-84. PubMed ID: 15105298
[TBL] [Abstract][Full Text] [Related]
14. [Medicines interacting with mitochondria: anti-ischemic effects of trimetazidine].
Spedding M; Tillement JP; Morin D; Le Ridant A
Therapie; 1999; 54(5):627-35. PubMed ID: 10667101
[TBL] [Abstract][Full Text] [Related]
15. [Ischemic heart disease and left ventricular dysfunction: the role of trimetazidine].
Belardinelli R
Ital Heart J; 2004 Mar; 5 Suppl 2():23S-28S. PubMed ID: 15074774
[TBL] [Abstract][Full Text] [Related]
16. Modulation of fatty acids oxidation in heart failure by selective pharmacological inhibition of 3-ketoacyl coenzyme-A thiolase.
Fragasso G; Spoladore R; Cuko A; Palloshi A
Curr Clin Pharmacol; 2007 Sep; 2(3):190-6. PubMed ID: 18690865
[TBL] [Abstract][Full Text] [Related]
17. Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism.
Clarke B; Wyatt KM; McCormack JG
J Mol Cell Cardiol; 1996 Feb; 28(2):341-50. PubMed ID: 8729066
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle's cycle.
Fang YH; Piao L; Hong Z; Toth PT; Marsboom G; Bache-Wiig P; Rehman J; Archer SL
J Mol Med (Berl); 2012 Jan; 90(1):31-43. PubMed ID: 21874543
[TBL] [Abstract][Full Text] [Related]
19. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts--role of late sodium current and intracellular ion accumulation.
Sossalla S; Wagner S; Rasenack EC; Ruff H; Weber SL; Schöndube FA; Tirilomis T; Tenderich G; Hasenfuss G; Belardinelli L; Maier LS
J Mol Cell Cardiol; 2008 Jul; 45(1):32-43. PubMed ID: 18439620
[TBL] [Abstract][Full Text] [Related]
20. Metabolic modulators for chronic cardiac ischemia.
Parang P; Singh B; Arora R
J Cardiovasc Pharmacol Ther; 2005 Dec; 10(4):217-23. PubMed ID: 16382258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
